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adherence/persistence and eight were able to improve the blood glucose levels of 
patients (double counting in three cases); ﬁ ve had no effect at all. Four dimensions of 
the methodological quality of AI programs were identiﬁ ed: 1) measurement of adher-
ence/persistence/clinical outcomes, 2) measurement of NA/NP causes, 3) use of effec-
tive/validated intervention measures; and 4) effective program evaluation. The authors 
deﬁ ned 5 detailed methodological requirements per dimension and, based on this, 
developed a corresponding scoring model (MIN Score 0, MAX score 20). All 19 AI 
programs were evaluated in the scoring model (average score 8.05): • Score <5: 3 
AI—no adherence/blood glucose level improvement; • Score 5–9: 8 AI—6 with 
improvement in both adherence and/or blood glucose levels; • Score >9: 8 AI—all 
improved adherence and/or blood glucose levels. CONCLUSIONS: The scoring model 
provides a starting point for the methodical evaluation of AI. However, further devel-
opment and testing of both the elements and construction is needed for medical indica-
tions other than diabetes type II.
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OBJECTIVES: To translate the MMAS into the Malaysian language, and to examine 
the psychometric properties of the Malaysian version of the MMAS among patients 
with type 2 diabetes, including its validity and reliability. METHODS: After obtaining 
permission, a standard “forward-backward” translation procedure was used to create 
the Malaysian version of the MMAS from the original English version. a convenience 
sample of 223 outpatients with type 2 diabetes was identiﬁ ed between May and Sep-
tember, 2009. All data were collected from the Penang General Hospital, Penang, 
Malaysia. Instruments consisted of the Malaysian version of MMAS, the Malaysian 
version of the old four-item Morisky scale and a sociodemographic questionnaire. 
Medical records were reviewed for hemoglobin A1C (HbA1C) levels and other clinical 
data. Reliability was tested for internal consistency using Cronbach’s α coefﬁ cient. 
Validity was conﬁ rmed using convergent and known group validity. RESULTS: 
Employing the recommended scoring method, the mean ± SD of MMAS scores was 
6.13 ± 1.72. Moderate internal consistency was found, (Cronbach’s α = 0.675), the 
test-retest reliability value by using Spearman’s rank correlation was 0.816 (P < 
0.001). a positive correlation between the eight- and four-item MMAS was found (r 
= 0.792; P < 0.01). For known group validity, a signiﬁ cant relationship between 
MMAS categories and HbA1c categories (χ2 = 20.261; P ≥ 0.001) was found. The 
MMAS sensitivity and speciﬁ city, with positive and negative predictive values were 
77.61%, 45.37%, 46.84% and 76.56%, respectively. CONCLUSIONS: The MMAS 
can be used for medication adherence measurement in diabetes. The ﬁ ndings of this 
validation study indicate that the Malaysian version of the MMAS is a reliable and 
valid measure of medication adherence which can now be used in clinical practice.
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OBJECTIVES: The last decade several studies have proven that lifestyle interventions 
can be effective for people with or at risk for diabetes. Because effectiveness of preven-
tive interventions is affected by non-participation (adherence), it is important to 
understand factors inﬂ uencing people’s willingness to participate in a lifestyle interven-
tion. Therefore, the aim of this exploratory analysis is to examine which factors of a 
lifestyle program inﬂ uence its valuation and willingness to participate. METHODS: 
We used conjoint analysis to empirically examine associations between the factors that 
inﬂ uence participation and participants’ valuation of an intervention and participants’ 
willingness to participate in a lifestyle intervention. For this purpose participants 
received a questionnaire with four hypothetical lifestyle interventions. They were 
asked to value the hypothetical scenarios with a grade from “1” to “10” and further-
more they were asked if they would be willing to participate in these hypothetical 
programs. Linear and logistic regression techniques were used for the analyses. 
RESULTS: The factors “group activity,” “counselling,” and “receiving money” were 
positively associated with the scores of the valuation of the programmes. Logistic 
regression analysis showed that money was the only factor that was independently 
associated with respondents’ willingness to participate in a lifestyle intervention. 
Subgroup analysis showed that receiving an amount of money was not associated with 
willingness to participate, but having to pay is negatively associated with participation 
in the lifestyle intervention. CONCLUSIONS: It appeared that only ﬁ nancial disincen-
tives were independently associated with willingness to participate in a lifestyle inter-
vention. Our conjoint analysis results suggest that ﬁ nancial incentives, in the form of 
bonuses, cannot be used to encourage people to participate in lifestyle interventions. 
Financial incentives, in the form of payments might however discourage participation, 
regardless of the content of the program.
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OBJECTIVES: To present HRQL data from a previously presented survey on T2D 
patients’ perceived quality of care in Stockholm, Sweden. METHODS: A postal survey 
including EQ-5D was distributed to 1000 members of the Stockholm Diabetic Patient 
Association and 1000 patients from ﬁ ve primary health care centers. Patients were 
randomly selected, >18 years, having a diabetes diagnosis. Analysis of variance was 
used to test the statistical hypothesis that patients within each subgroup had equal 
mean utility. RESULTS: Response rate was 65% (1319/2000 questionnaires). T2D 
diagnose was reported for 961 respondents of which 858 completed the EQ-5D 
questionnaire. Mean age 69 years, 48.5 % female, BMI 28.4 kg/m2, mean duration 
of T2D 11.3 years. Overall, the mean (SD) utility was 0.765 (0.260) and the current 
health status reported on the VAS scale was 0.727 (0.189). Patients without any 
hypoglycemic episode the previous month had a utility of 0.799 while those with 1, 
2–5 or >5 episodes reported 0.774, 0.687 and 0.633, respectively. More than one 
hypoglycemic episode resulted in signiﬁ cantly lower utility compared to none or only 
one episode (P < 0.0001). The utility of obese patients, 0.704, was signiﬁ cantly lower 
than for patients of normal weight, 0.806, or overweight, 0.790 (P < 0.0001). The 
utility of patients not considering themselves responsible for the management of their 
T2D was signiﬁ cantly lower, 0.608, compared to patients taking a limited, 0.774, or 
full, 0.759, responsibility (P = 0.0005). Patients considering themselves having insuf-
ﬁ cient knowledge to cope with their T2D reported a lower utility, 0.689, compared 
to patients with sufﬁ cient knowledge, 0.789 (P < 0.0001). Male respondents had a 
higher utility, 0.796, compared to females, 0.731 (P = 0.0002). CONCLUSIONS: 
Experience of hypoglycemic episodes, obesity, gender, patients’ perception of personal 
responsibility and perceived knowledge about type 2 diabetes has signiﬁ cant impact 
on health related quality of life in patients with type 2 diabetes.
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OBJECTIVES: Cost-utility analysis in diabetes requires utility estimates for diabetic 
complications. Models frequently rely on UKPDS data. UK requirements for prefer-
ence elicitation have changed since UKPDS publication. We conducted a systematic 
review of the literature to identify utility values for diabetes complications suitable for 
use in Health Technology Assessment (HTA). METHODS: A systematic search of 
online databases was conducted using key words relating to diabetes, major complica-
tions, utility assessment and quality of life. Reference lists of identiﬁ ed citations were 
reviewed. Studies reporting utility single-index measures in patients with any of 33 
pre-speciﬁ ed diabetes related states were included: states considered were diabetic 
complications and adverse events associated with anti-diabetic therapies (AEs). Papers 
were qualitatively assessed: criteria included relevance of studied population to Type 
1 or Type 2 diabetes, sample size, methodological quality and consistency with current 
UK HTA guidelines. Comorbidity is common in diabetes: methodology papers 
addressing combination of utility values were identiﬁ ed in a structured search and 
reviewed. RESULTS: The search returned 3024 hits, 169 articles were reviewed and 
32 publications were identiﬁ ed as suitable for review. Utility or disutility values suit-
able for UK HTA were obtained for 23 diabetes states. For 10 complications, including 
late stage renal disease and some AEs, no utility value were identiﬁ ed that met UK 
HTA criteria. There is no consensus in the literature on how utility measures should 
be combined in patients with more than one complication. CONCLUSIONS: We 
identiﬁ ed a set of utility values suitable for economic analysis for HTA in diabetes. 
To further inform UK HTA, additional research should create robust utility values for 
diabetic renal disease, and evaluate the empirical accuracy of alternative methods of 
combining utility values in patients with multiple complications.
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OBJECTIVES: The study is to measure the health-related quality of life (HRQOL) in 
type 2 diabetes mellitus (T2DM) patients with oral anti-diabetic drugs (OADs) therapy 
using the Chinese version of EQ-5D, and examine their health status. METHODS: 
The study was a cross-sectional survey conducted at 75 hospitals in nine cities in 
China. There were 9577 T2DM patients administered with OADs therapy completed 
the questionnaires. The survey period was from December 3rd, 2008 to July 31st, 2009. 
Patients evaluated their health status using ﬁ ve dimensions (5D) and a visual analog 
scale (VAS). Descriptive statistics was used to describe patients’ demographic charac-
teristics, duration of the disease, the frequency of 5D responses and VAS score. STATA 
9.2 was used for the analyses. RESULTS: The mean age of patients (±SD) was 59.5 
± 12.7 years. 51.1% were male. The mean body mass index (±SD) was 24.3 ± 3.4 kg/
m2. The mean duration of disease (±SD) was 7.9 ± 6.3 years. For the ﬁ ve dimensions 
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of EQ-5D, the frequency of T2DM patients responding as having “some problem” 
and “extreme problem” was 4.6% and 1.6% for mobility, 7.9% and 1.4% for self-
care, 13.9% and 1.7% for usual activities, 27.5% and 1.1% for pain/discomfort, and 
26.6% and 1.3% for anxiety/depression, respectively. The mean VAS score (±SD) of 
patients was 70.4 ± 15.1. CONCLUSIONS: The rates of T2DM patients with “some 
problem” in pain/discomfort, and anxiety/depression were relatively high; rate with 
“extreme problem” for usual activities was also higher than other dimensions. The 
results of 5D were consistent with the low VAS score. These ﬁ ndings imply that there 
was a signiﬁ cant impact on the health status of T2DM patients with OADs therapy 
due to pain/discomfort, and anxiety/depression. It underscores the urgent need to 
adopt effective measures toward prevention and control of diabetes to improve 
patients’ quality of life.
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OBJECTIVES: The objective of this study was to elicit quality-adjusted life-year 
(QALY) weights for the different severity levels of diabetic retinopathy (DR) and to 
evaluate the adequacy of using certain health-related quality of life (HRQoL) instru-
ments for this purpose. METHODS: The study population comprises 151 patients 
with diabetes (type 1 and 2) that either attended the eye clinic at Linköping University 
Hospital or were registered at any of the two vision centrals in Östergötland County, 
Sweden. Participants were interviewed over the phone using time trade-off (TTO) 
questions, the EuroQol Health Questionnaire (EQ-5D), the Health Utilities Index 
Mark III (HUI-3) and the National Eye Institute Visual Function Questionnaire (NEI-
VFQ-25). The effect of other variables than DR on QALY weights was investigated 
using ANCOVA and the generic instruments were tested for correlation with NEI-
VFQ-25. RESULTS: The ranges of the QALY weights estimated with the three generic 
instruments were for no DR, BR, PDR, maculopathy and legal blindness 0.81–0.88, 
0.72–0.78, 0.75–0.82, 0.74–0.81 and 0.39–0.68 respectively. In general, the differ-
ences in QALY weights between the different severity levels were reduced when 
adjusted for clinical characteristics and co-morbidities. The difference in QALY 
weights between the patients with no DR and legal blindness was signiﬁ cant for all 
instruments. The correlations between the results from NEI-VFQ-25 and TTO, EQ-5D 
score, EQ-5D VAS and HUI-3 were 0.27, 0.31, 0.38 and 0.68 respectively. CONCLU-
SIONS: This study presents QALY weights for different severity levels of DR, which 
can be used in cost-effectiveness analyses of interventions directed to DR. Of the 
instruments we used, HUI-3 seems to be the most sensitive to changes in HRQoL due 
to progression of DR.
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OBJECTIVES: The QoL-AGHDA is the ﬁ rst true quality of life (QoL) measure for 
adult growth hormone deﬁ ciency and is widely used in clinical practice and trials. In 
the UK NICE advises that scores on the QoL-AGHDA should be used to guide treat-
ment selection. The scale has good psychometric properties and has been shown to 
be responsive to changes in disease severity. The objective of the study was to adapt 
the QoL-AGHDA for the Czech Republic, Poland, Serbia, Slovakia and Brazil. 
METHODS: The adaptation in each country required three stages: Translation, cogni-
tive debrieﬁ ng and a validation survey. The dual panel translation method was used 
to ensure the items were translated accurately and expressed in everyday language. 
Cognitive-debrieﬁ ng interviews with local patients assessed face and content validity. 
The validation survey tested the psychometric properties of the new scales and 
included the Nottingham Health Proﬁ le (NHP) as a comparator measure. RESULTS: 
Validation data are not available for Slovakia. Mean scores on the new versions of 
the QoL-AGHDA ranged from 6.2 to 11.8 (maximum possible = 25). Internal con-
sistency ranged from 0.89–0.91 and test-retest reliability from 0.88–0.93. QoL-
AGHDA scores were statistically signiﬁ cantly related to; perceived general health and 
level of fatigue in the Czech Republic, perceived physical activity and level of fatigue 
in Poland and Serbia and to perceived general health and rated QoL in Brazil. Across 
the countries mean correlations with NHP sections were (as expected) highest with 
energy level and emotional reactions (correlations 0.68–0.83) and lowest with sleep 
disturbance and pain (correlations 0.38–0.46). CONCLUSIONS: This study indicates 
that (with the exception of Slovakia which requires further validation) the new lan-
guage versions of the QoL-AGHDA meet the standards of the original UK version 
and the other 9 existing versions. The new adaptations represent valid and reliable 
tools for measuring QoL in international clinical trials.
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OBJECTIVES: Hypoglycaemia can be a side effect of glucose-lowering treatment in 
patients with type 2 diabetes (T2D) that may counterbalance the beneﬁ cial effects of 
diabetes control. PANORAMA is a large (n = 5156) pan-European cross-sectional 
survey (NCT00916513) of patients assessing patient reported outcomes and glycaemic 
control. This subgroup analysis compared rates of severe and non-severe hypoglycae-
mic events in patients taking different pharmacological treatment regimens. 
METHODS: Patients with T2D were randomly or consecutively selected from medical 
practices in eight countries. Patients were aged ≥40 years, with T2D diagnosed >1 
year and a clinic medical record available >1 year. All patients received dietary/exercise 
advice and most were also taking either oral antidiabetic drugs (OADs) and/or inject-
ables (insulin and/or GLP-1 receptor agonists). Patients included in this subgroup 
analysis had been taking the same pharmacological treatment regimen for ≥12 months. 
Patient-reported frequency of severe (symptomatic episodes requiring external assis-
tance) and non-severe hypoglycaemic episodes in the past year were examined. 
RESULTS: In this subgroup analysis 3106 patients were evaluated including: 1346 
taking only OADs without secretagogues; 1452 taking only OADs including secreta-
gogues (sulphonylurea/glinides) and 308 on insulin alone. The percentages of patients 
experiencing >1 non-severe hypoglycaemic episode in each treatment group were: 
8.9% for patients taking OADs without secretagogues; 17.5% for patients taking 
OADs including secretagogues and 47.4% for patients using insulin alone. The dif-
ferences between these three treatment categories (pair-wise comparisons) were highly 
signiﬁ cant (P < 0.001). The percentage of patients reporting ≥1 severe hypoglycaemic 
episode was greater for OADs including secretagogues versus no secretagogues (3.0% 
versus 1.3%; P = 0.011) and for insulin alone versus OADs including secretagogues 
(13.7% versus 3.0%; P < 0.001). CONCLUSIONS: Among patients with T2D on 
glucose-lowering medication, rates of non-severe and severe hypoglycaemic episodes 
were lowest amongst patients treated with OADs not including secretagogues and 
highest among patients treated with insulin alone.
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OBJECTIVES: Understanding the perspectives of Type 2 Diabetes (T2D) patients on 
hypoglycemia is important, in order to understand the burden of the disease and its 
treatment, and to develop improved outcome measures. The goal of this project was 
to identify key hypoglycemia-related concepts among T2D patients using qualitative 
interviews. METHODS: Participants were 19 T2D patients who were prescribed: 1) 
an oral anti-diabetic (OAD) and had been diagnosed with T2D in the past 3 years (n 
= 11); 2) a sulfonylurea (SU) or thiazolidinedione (TZD) that caused weight gain, 
following the failure of an OAD in the last year (n = 5); or 3) an incretin mimetic that 
caused weight loss, following the failure of an OAD in the last year (n = 3). One-hour 
in-person interviews were conducted using a semi-structured interview guide. Inter-
views were coded using ATLAS.ti software and code frequency was used to identify 
key experiences. RESULTS: Patients were 54.4 years of age on average and 63% were 
female. Tremor, sweating, and dizziness were the most commonly noted symptoms of 
hypoglycemia; all ﬁ ve of the patients on an SU or TZD reported experiencing tremor. 
Patients reported concerns about rare, severe events, such as passing out. Patients 
generally did not report that their lives were substantially impacted by hypoglycemia, 
but completing compensatory behaviors to prevent hypoglycemia emerged as an 
important theme (keeping glucotabs in multiple locations, eating large meals). CON-
CLUSIONS: Hypoglycemia has a negative impact on patients with T2D. Many report 
experiencing hypoglycemia symptoms, and, although T2D patients do not often report 
anxiety about hypoglycemia, several reported concerns about the consequences of 
severe events. Patients also engage in compensatory behaviors, which suggests that 
avoiding hypoglycemia is important. Further reﬁ nement of the concepts associated 
with the patient’s experience of hypoglycemia may yield new PRO instruments that 
can be implemented in clinical trials with T2D patients.
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OBJECTIVES: Maintaining a healthy weight is important in the management of 
T2DM. We investigated the relationship between weight and patient concerns in rela-
tion to overall health-related well-being and function among those with T2DM. 
